Neurodegenerative disorder

4 trials 1 recruiting MedDRA PT
4 Registered trials
1 Recruiting
4 Unique sponsors
3 Unique IMPs
3 Commercial trials
Drug classes (ATC)
— ATC code not specified 2
N Neurology/Psychiatry (ATC N) 1
V Various (ATC V) 1
Mechanism of action (INN-stem analysis)
Unknown / small molecule 2 substances
Monoclonal antibody (neural) 1 substance
Phase III: 1 Phase II: 1 Phase I: 1 Phase I (Other): 1

Filter these 4 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 4 trials

Phase III

1 trial
  • Alector LLC Commercial
    LATOZINEMAB
    2023-506805-20-01 7 countries 2024 n=32 Orphan
    Ended

Phase II

1 trial
  • Region Skane Academic
    2-(6-[18F]FLUORO-PYRIDIN-3-YL)-9H-DIPYRIDO[2,3-B:3',4'-D]PYRROLE; FLUTEMETAMOL (18F)
    2024-511842-38-00 1 country 2017 n=2,450
    Recruiting

Phase I

1 trial
  • Eli Lilly & Co. Commercial
    IMP not specified
    2023-504838-21-00 1 country 2025 n=69
    Ended

Phase I (Other)

1 trial
  • Integrative Research Laboratories Sweden AB Commercial
    IMP not specified
    2024-515124-36-00 1 country 2024 n=12
    Ended
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Eli Lilly & Co. Commercial 1 Phase I 0
Integrative Research Laboratories Sweden AB Commercial 1 Phase I (Other) 0
Alector LLC Commercial 1 Phase III 0
Region Skane Academic 1 Phase II 1
New trials by year
2024
2
2025
1
← All indication landscapes